Utility of repeat genotypic resistance testing and clinical response in patients with three class resistance and virologic treatment failure

AIDS Patient Care and STDs

Volumn 21, Issue 8, 2007, Pages 544-550

  Badri, Sheila M ^a,b,c   Adeyemi, Oluwatoyin M ^a,b,c   Max, Blake E ^c,d   Hota, Bala N ^a,b,c   Barker, David E ^a,b,c  

^a Jr Hospital of Cook County   (United States)

^b RUSH MEDICAL COLLEGE   (United States)

^c Department of Medicine   (United States)

^d UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; AMPRENAVIR; ANTIRETROVIRUS AGENT; DIDANOSINE; EFAVIRENZ; INDINAVIR; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RITONAVIR; SAQUINAVIR; STAVUDINE; TENOFOVIR; VIRUS RNA; ZIDOVUDINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; PROTEINASE; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; CONTROLLED STUDY; FEMALE; GENE SEQUENCE; GENOTYPE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; POPULATION RESEARCH; TIME; TREATMENT FAILURE; TREATMENT RESPONSE; VIROLOGY; VIRUS LOAD; ANTIBIOTIC RESISTANCE; BLOOD; DRUG COMBINATION; DRUG EFFECT; ENZYMOLOGY; GENETICS; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOLOGY; MICROBIOLOGICAL EXAMINATION; MIDDLE AGED; MUTATION; TREATMENT OUTCOME;

ADULT; ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; DRUG RESISTANCE, VIRAL; DRUG THERAPY, COMBINATION; FEMALE; GENOTYPE; HIV INFECTIONS; HIV PROTEASE; HIV-1; HIV-1 REVERSE TRANSCRIPTASE; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; MUTATION; REVERSE TRANSCRIPTASE INHIBITORS; RNA, VIRAL; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 35448999358     PISSN: 10872914     EISSN: None     Source Type: Journal    
DOI: 10.1089/apc.2006.0156     Document Type: Article

References (15)

1. Durant J, Clevenbergh P, Halfon P, et al. Drug-resistance genotyping in HIV-1 therapy: The VIRADAPT randomized controlled trial. Lancet 1999;353:2195-2199.
2. Baxter JD, Mayers DL, Wentworth DN, et al. A randomized study of antiretroviral management based on plasma genotypic antiretroviral resistance testing in patients failing therapy. CPCRA 046 study team for the Terry Beirn Community Programs for Clinical Research on AIDS. AIDS 2000;14:F83-93.
3. Tural C, Ruiz L, Holtzer C, et al. Clinical utility of HIV-1 genotyping and expert advice: the HAVANA trial. AIDS 2002;16:209-218.
4. Little SJ, Holte S, Routy JP, et al. Antiretroviral-drug resistance among patients recently infected with HIV. N Engl J Med 2002;347:385-394.
5. Hirsch MS, Brun-Vezinet F, Clotet B, et al. Antiretroviral drug resistance testing in adults infected with human immunodeficiency virus type 1: 2003 recommendations of an International AIDS Society-USA panel. Clin Infect Dis 2003;37:113-128.
6. US Department of Health and Human Services and Henry J Kaiser Family Foundation. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents, April 7, 2005 revision. www.hivatis.org/ trtgdlns.html (Last accessed June 10, 2005). Badri SM, Adeyemi OM, Max BE, Zagorski BM, Barker DE. How does expert advise impact genotypic resistance testing in clinical practice? Clin Infect Dis 2003;37:708-713.
7. Cingolani A, Antinori A, Rizzo MG, et al. Usefulness of monitoring HIV drug resistance and adherence in individuals failing highly active antiretroviral therapy: A randomized study (ARGENTA). AIDS 2002; 16:369-379.
8. Meynard JL, Vray M, Morand-Joubert L, et al. Phenotypic or genotypic resistnace testinf for choosing antiretroviral therapy after treatment failure: A randomized trial. AIDS 2002;16:727-736.
9. Wegner SA, Wallace MR, Aronson NE, et al. Long-term efficacy of routine access to antiretroviral-resistance testing in HIV-type-infected patients: Results of the clinical efficacy of resistance testing trial. Clin Infect Dis 2004;38:723-730.
10. Johnson VA, Brun-Vezinet F, Clotet B, et al. International AIDS Society-USA Drug Resistance Mutations Group. Drug resistance mutations in HIV-1. Top HIV Med 2004;11:215-221.
11. Harrigan PR, Wynhoven B, Brumme ZL, et al. HIV-1 drug resistance: Degree of underestimation by a cross-sectional versus a longitudinal testing approach. J Infect Dis 2005;191:1325-1330.
12. Svedhem V, Lindkvist A, Lidman K, Sonnerborg A. Persistence of earlier HIV-1 drug resistance mutations at new treatment failure. J Med Virol 2002;68:473-78.
13. Deeks SG, Wrin T, Liegler T, et al. Virologic and immunologic consequences of discontinuing combination antiretroviral-therapy in HIV-infected patients with detectable viremia. N Engl J Med 2001;34:472-440.
14. + T cell response after virologic failure of protease inhibitor-based regimens in patients with human immunodeficiency virus infection. J Infect Dis 2000;181:946-953.
15. Lucas GM, Gallant JE, Moore RD. Relationship between drug resistance and HIV-1 disease progression or death in patients undergoing resistance testing. AIDS 2004;18:1539-1548.